465 related articles for article (PubMed ID: 33549037)
41. Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction.
Raghav K; French JT; Ueno NT; Lei X; Krishnamurthy S; Reuben JM; Valero V; Ibrahim NK
PLoS One; 2016; 11(1):e0145534. PubMed ID: 26752563
[TBL] [Abstract][Full Text] [Related]
42. Post-mastectomy immediate breast reconstruction is oncologically safe in well-selected T4 locally advanced breast cancer: a large population-based study and matched case-control analysis.
Wang M; Chen H; Wu K; Ding A; Zhang P; Zhang M
Breast Cancer Res Treat; 2019 Jul; 176(2):337-347. PubMed ID: 31020469
[TBL] [Abstract][Full Text] [Related]
43. Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers.
Kai M; Kogawa T; Liu DD; Fouad TM; Kai K; Niikura N; Hsu L; Willey JS; Theriault RL; Valero V; Ueno NT
Clin Breast Cancer; 2015 Feb; 15(1):37-42. PubMed ID: 25258308
[TBL] [Abstract][Full Text] [Related]
44. Initial response to chemotherapy, not delay in diagnosis, predicts overall survival in inflammatory breast cancer cases.
Hoffman HJ; Khan A; Ajmera KM; Zolfaghari L; Schenfeld JR; Levine PH
Am J Clin Oncol; 2014 Aug; 37(4):315-21. PubMed ID: 23241503
[TBL] [Abstract][Full Text] [Related]
45. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
46. Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer.
Yao Y; Chu Y; Xu B; Hu Q; Song Q
Cancer Med; 2019 Feb; 8(2):554-563. PubMed ID: 30632300
[TBL] [Abstract][Full Text] [Related]
47. Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy.
Tsai CJ; Li J; Gonzalez-Angulo AM; Allen PK; Woodward WA; Ueno NT; Lucci A; Krishnamurthy S; Gong Y; Yang W; Cristofanilli M; Valero V; Buchholz TA
Am J Clin Oncol; 2015 Jun; 38(3):242-7. PubMed ID: 23648437
[TBL] [Abstract][Full Text] [Related]
48. Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO).
Slaoui M; Zoure AA; Mouh FZ; Bensouda Y; El Mzibri M; Bakri Y; Amrani M
BMC Cancer; 2018 Jul; 18(1):713. PubMed ID: 29976157
[TBL] [Abstract][Full Text] [Related]
49. A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer.
Wang Z; Wang H; Ding X; Chen X; Shen K
Ther Adv Med Oncol; 2020; 12():1758835920932674. PubMed ID: 32550867
[TBL] [Abstract][Full Text] [Related]
50. A high neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are associated with a worse outcome in inflammatory breast cancer.
Van Berckelaer C; Van Geyt M; Linders S; Rypens C; Trinh XB; Tjalma WAA; Van Laere S; Colpaert C; Dirix L; van Dam PA
Breast; 2020 Oct; 53():212-220. PubMed ID: 32890963
[TBL] [Abstract][Full Text] [Related]
51. The Extent of Axillary Surgery Is Associated With Breast Cancer-specific Survival in T1-2 Breast Cancer Patients With 1 or 2 Positive Lymph Nodes: A SEER-Population Study.
Li S; Liu F; Chen K; Rao N; Xie Y; Su F; Zhu L
Medicine (Baltimore); 2016 Apr; 95(14):e3254. PubMed ID: 27057872
[TBL] [Abstract][Full Text] [Related]
52. Nomograms for Estimating Cause-Specific Death Rates of Patients With Inflammatory Breast Cancer: A Competing-Risks Analysis.
Xu F; Yang J; Han D; Huang Q; Li C; Zheng S; Wang H; Lyu J
Technol Cancer Res Treat; 2021; 20():15330338211016371. PubMed ID: 34013802
[TBL] [Abstract][Full Text] [Related]
53. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Kogawa T; Fujii T; Wu J; Harano K; Fouad TM; Liu DD; Shen Y; Masuda H; Krishnamurthy S; Chavez-MacGregor M; Lim B; Murthy RK; Valero V; Tripathy D; Ueno NT
Oncologist; 2020 Jun; 25(6):e909-e919. PubMed ID: 32003919
[TBL] [Abstract][Full Text] [Related]
54. The Prognostic Significance of the Oncotype DX Recurrence Score in T
Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
[TBL] [Abstract][Full Text] [Related]
55. Nomogram for predicting the overall survival of patients with inflammatory breast cancer: A SEER-based study.
Pan X; Yang W; Chen Y; Tong L; Li C; Li H
Breast; 2019 Oct; 47():56-61. PubMed ID: 31351202
[TBL] [Abstract][Full Text] [Related]
56. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
57. Racial disparities in treatment and outcomes between non-Hispanic Black and non-Hispanic White women with nonmetastatic inflammatory breast cancer.
Carbajal-Ochoa WH; Johnson D; Alvarez A; Bernal AM; Anampa JD
Breast Cancer Res Treat; 2023 Sep; 201(2):275-287. PubMed ID: 37442877
[TBL] [Abstract][Full Text] [Related]
58. Modern outcomes of inflammatory breast cancer.
Rehman S; Reddy CA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):619-24. PubMed ID: 22445003
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
Du ZL; Wang Y; Wang DY; Zhang L; Bian ZM; Deng Y; Xu CS; Lin DC; Xie L; Jia Y; Gao JD; Zhang BL
Breast Cancer Res Treat; 2020 Sep; 183(2):429-438. PubMed ID: 32647940
[TBL] [Abstract][Full Text] [Related]
60. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
